Live prices from 2 UK suppliers, from £39.95, compared side by side so you never overpay.
Copy the code — you'll paste it at checkout.
with our exclusive code
You're about to visit an external supplier
with our exclusive code
By clicking "Continue", you acknowledge that you understand and accept the above. Read our full disclosure.
Compare 1 price for EPO. Cheapest: £98.00. Average: £98.00.
| Compare | Visit | |||||||
|---|---|---|---|---|---|---|---|---|
| £98.00 | — | Out of Stock | Free |
Lab Tested
|
— | Unavailable |
More ways to compare EPO
Different views of the same live UK pricing, tuned for how you like to shop.
Compare another peptide
All purchases are made directly from third-party suppliers; your relationship is solely with them. We accept no liability for the quality, purity, or legality of any products listed.
We may earn a commission when you click through to a supplier and make a purchase. This does not affect pricing information displayed.
By using this site you accept responsibility for ensuring purchases comply with applicable laws in your jurisdiction. Read our full disclosure.
EPO | Red Blood Cell Stimulating Hormone
Erythropoietin (EPO) is an essential glycoprotein hormone that stimulates red blood cell production. Naturally produced by the kidneys in response to low oxygen levels, recombinant human EPO is FDA-approved for treating anemia in chronic kidney disease and chemotherapy patients. EPO binding to receptors on bone marrow cells promotes survival and maturation of red blood cell precursors, increasing oxygen-carrying capacity. Due to performance-enhancing effects, it is banned in competitive sports.
EPO binds to erythropoietin receptors (EPOR) on erythroid progenitor cells in bone marrow, activating three interconnected signaling pathways: JAK2/STAT5, PI3K/AKT, and RAS/MAPK. This promotes survival of red blood cell precursors by protecting them from apoptosis, accelerates proliferation and differentiation of erythroid cells, and increases hemoglobin production. Under hypoxic stress, endogenous EPO production can increase up to 1000-fold, demonstrating the body's powerful oxygen-sensing regulatory system.
Primary FDA-approved indication for anemia secondary to chronic kidney disease.
FDA-approved for treating anemia in cancer patients receiving chemotherapy.
Used to reduce need for blood transfusions in certain surgical settings.
Increases oxygen delivery to muscles, improving endurance capacity. Banned by WADA.
May accelerate adaptation to high altitude by increasing red blood cell mass.
EPO is administered via subcutaneous or intravenous injection. Medical use requires prescription and monitoring. Dosing is individualized based on hemoglobin levels, with targets typically kept below 11-12 g/dL to minimize cardiovascular risks.
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| CKD Anemia (medical) | 50-100 IU/kg | 3x weekly | SubQ or IV |
| Chemotherapy Anemia (medical) | 150-300 IU/kg | 3x weekly | SubQ |
| Maintenance (medical) | Individualized | 1-3x weekly | SubQ |
Iron is essential for hemoglobin production; often co-administered with EPO therapy.
Different mechanisms; no known interactions.
Different mechanisms; no known interactions.
Bone marrow stimulation begins
Reticulocyte count increases
Hemoglobin begins rising
Target hemoglobin achieved with proper dosing
PMC/NCBI
Comprehensive review of EPO's oxygen-sensing mechanism and regulation of RBC production.
StatPearls (NCBI Bookshelf)
FDA-approved indications include CKD anemia and chemotherapy-induced anemia. Risks increase when hemoglobin exceeds 11-12 g/dL.
PMC
rHuEPO increases O2 supply to muscles and boosts performance in endurance sports.
PubMed
EPO promotes survival of erythroid progenitors by protecting from apoptosis.
Be the first to know when prices drop on your favourite peptides
No spam. Unsubscribe anytime. We respect your privacy.